114 related articles for article (PubMed ID: 17379323)
1. Inhibition of replication of primary HIV-1 isolates in huPBL-NOD/Scid mice by antibodies from HIV-1 infected patients.
Steyaert S; Heyndrickx L; Verhoye L; Vermoesen T; Donners H; Fransen K; Van Wanzeele F; Vandergucht B; Vanham G; Leroux-Roels G; Vanlandschoot P
Antiviral Res; 2007 Aug; 75(2):129-38. PubMed ID: 17379323
[TBL] [Abstract][Full Text] [Related]
2. Cocaine and sigma-1 receptors modulate HIV infection, chemokine receptors, and the HPA axis in the huPBL-SCID model.
Roth MD; Whittaker KM; Choi R; Tashkin DP; Baldwin GC
J Leukoc Biol; 2005 Dec; 78(6):1198-203. PubMed ID: 16204638
[TBL] [Abstract][Full Text] [Related]
3. Anticardiolipin antibodies in HIV infection are independently associated with antibodies to the membrane proximal external region of gp41 and with cell-associated HIV DNA and immune activation.
Martinez V; Diemert MC; Braibant M; Potard V; Charuel JL; Barin F; Costagliola D; Caumes E; Clauvel JP; Autran B; Musset L;
Clin Infect Dis; 2009 Jan; 48(1):123-32. PubMed ID: 19035778
[TBL] [Abstract][Full Text] [Related]
4. Dichotomy in cross-clade reactivity and neutralization by HIV-1 sera: Implications for active and passive immunotherapy.
Cavacini LA; Duval M; Patil A; Wood C; Mayer KH; Ruprecht RM; Posner MR
J Med Virol; 2005 Jun; 76(2):146-52. PubMed ID: 15834877
[TBL] [Abstract][Full Text] [Related]
5. In SCID-hu mice, passive transfer of a humanized antibody prevents infection and atrophic change of medulla in human thymic implant due to intravenous inoculation of primary HIV-1 isolate.
Okamoto Y; Eda Y; Ogura A; Shibata S; Amagai T; Katsura Y; Asano T; Kimachi K; Makizumi K; Honda M
J Immunol; 1998 Jan; 160(1):69-76. PubMed ID: 9551957
[TBL] [Abstract][Full Text] [Related]
6. Dynamics of memory and naïve CD8+ T lymphocytes in humanized NOD/SCID/IL-2Rgammanull mice infected with CCR5-tropic HIV-1.
Sato K; Nie C; Misawa N; Tanaka Y; Ito M; Koyanagi Y
Vaccine; 2010 May; 28 Suppl 2():B32-7. PubMed ID: 20510741
[TBL] [Abstract][Full Text] [Related]
7. Ex vivo neutralization of HIV-1 quasi-species by a broadly reactive humanized monoclonal antibody KD-247.
Matsushita S; Takahama S; Shibata J; Kimura T; Shiozaki K; Eda Y; Koito A; Murakami T; Yoshimura K
Hum Antibodies; 2005; 14(3-4):81-8. PubMed ID: 16720978
[TBL] [Abstract][Full Text] [Related]
8. HIV sensitivity to neutralization is determined by target and virus producer cell properties.
Mann AM; Rusert P; Berlinger L; Kuster H; Günthard HF; Trkola A
AIDS; 2009 Aug; 23(13):1659-67. PubMed ID: 19581791
[TBL] [Abstract][Full Text] [Related]
9. Inter-subtype cross-neutralizing antibodies recognize epitopes on cell-associated HIV-1 virions.
Donners H; Davis D; Willems B; van der Groen G
J Med Virol; 2003 Feb; 69(2):173-81. PubMed ID: 12683404
[TBL] [Abstract][Full Text] [Related]
10. Tetrahydrocannabinol suppresses immune function and enhances HIV replication in the huPBL-SCID mouse.
Roth MD; Tashkin DP; Whittaker KM; Choi R; Baldwin GC
Life Sci; 2005 Aug; 77(14):1711-22. PubMed ID: 15964028
[TBL] [Abstract][Full Text] [Related]
11. Pertussis toxin B-oligomer inhibits HIV infection and replication in hu-PBL-SCID mice.
Lapenta C; Spada M; Santini SM; Racca S; Dorigatti F; Poli G; Belardelli F; Alfano M
Int Immunol; 2005 Apr; 17(4):469-75. PubMed ID: 15746245
[TBL] [Abstract][Full Text] [Related]
12. Cross-clade neutralization patterns among HIV-1 strains from the six major clades of the pandemic evaluated and compared in two different models.
Brown BK; Wieczorek L; Sanders-Buell E; Rosa Borges A; Robb ML; Birx DL; Michael NL; McCutchan FE; Polonis VR
Virology; 2008 Jun; 375(2):529-38. PubMed ID: 18433824
[TBL] [Abstract][Full Text] [Related]
13. Elimination of HIV-1 infection by treatment with a doxorubicin-conjugated anti-envelope antibody.
Johansson S; Goldenberg DM; Griffiths GL; Wahren B; Hinkula J
AIDS; 2006 Oct; 20(15):1911-5. PubMed ID: 16988511
[TBL] [Abstract][Full Text] [Related]
14. Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies.
Trkola A; Kuster H; Rusert P; Joos B; Fischer M; Leemann C; Manrique A; Huber M; Rehr M; Oxenius A; Weber R; Stiegler G; Vcelar B; Katinger H; Aceto L; Günthard HF
Nat Med; 2005 Jun; 11(6):615-22. PubMed ID: 15880120
[TBL] [Abstract][Full Text] [Related]
15. Cocaine enhances human immunodeficiency virus replication in a model of severe combined immunodeficient mice implanted with human peripheral blood leukocytes.
Roth MD; Tashkin DP; Choi R; Jamieson BD; Zack JA; Baldwin GC
J Infect Dis; 2002 Mar; 185(5):701-5. PubMed ID: 11865430
[TBL] [Abstract][Full Text] [Related]
16. Human antibodies that neutralize primary human immunodeficiency virus type 1 in vitro do not provide protection in an in vivo model.
Schutten M; Tenner-Racz K; Racz P; van Bekkum DW; Osterhaus AD
J Gen Virol; 1996 Aug; 77 ( Pt 8)():1667-75. PubMed ID: 8760413
[TBL] [Abstract][Full Text] [Related]
17. Revisiting the role of neutralizing antibodies in mother-to-child transmission of HIV-1.
Barin F; Jourdain G; Brunet S; Ngo-Giang-Huong N; Weerawatgoompa S; Karnchanamayul W; Ariyadej S; Hansudewechakul R; Achalapong J; Yuthavisuthi P; Ngampiyaskul C; Bhakeecheep S; Hemwutthiphan C; Lallemant M;
J Infect Dis; 2006 Jun; 193(11):1504-11. PubMed ID: 16652277
[TBL] [Abstract][Full Text] [Related]
18. Defining antibody protection against HIV-1 transmission in Hu-PBL-SCID mice.
Koup RA; Safrit JT; Weir R; Gauduin MC
Semin Immunol; 1996 Aug; 8(4):263-8. PubMed ID: 8883150
[TBL] [Abstract][Full Text] [Related]
19. Changing sensitivity to broadly neutralizing antibodies b12, 2G12, 2F5, and 4E10 of primary subtype B human immunodeficiency virus type 1 variants in the natural course of infection.
Bunnik EM; van Gils MJ; Lobbrecht MS; Pisas L; van Nuenen AC; Schuitemaker H
Virology; 2009 Aug; 390(2):348-55. PubMed ID: 19539340
[TBL] [Abstract][Full Text] [Related]
20. Neutralizing activity and cellular immune responses induced in mice after immunization with apoptotic HIV-1/murine leukemia virus infected cells.
Hinkula J; Walther-Jallow L; Laurén A; Mäkitalo B; Oberg M; Wahren B; Fenyö EM; Spetz AL
Vaccine; 2009 Oct; 27(46):6424-31. PubMed ID: 19549607
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
